BONE BIOLOGICS CORP
BBLGNASDAQTrading Snapshot
- Day Range
- $0.48 – $0.49
- 52-Week Range
- $0.43 – $2.89
- Volume
- $2.65B
- Avg Volume
- $2.93B
- Shares Outstanding
- 1.8M
- Next Earnings
- Nov 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $103,946
- Last Q Revenue
- $28,641
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.61
- Dividend Yield
- —
- Dilution (1yr)
- −60.2%
Why Investors Own BBLG
- ✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BONE BIOLOGICS CORP
BBLG
StockOtter · stockotter.spaceAbout BONE BIOLOGICS CORP
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Short Interest in Bone Biologics Corp. (NASDAQ:BBLG) Drops By 76.4%
Bone Biologics Corp. (NASDAQ: BBLG - Get Free Report) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totaling 36,999 shares, a decrease of 76.4% from the Augus
Bone Biologics Expands Trial Sites
BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced tha
Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced tha
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
BURLINGTON, Mass, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announces th
Bone Biologics (BBLG) to Announce Earnings on Thursday
Bone Biologics (NASDAQ: BBLG - Get Free Report) will likely be issuing its results before the market opens on Thursday, August 13th. Analysts expect Bone Biologics to announce earnings of ($0.39) per share for the quarte
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets, today issued a sha